Clinical Trial Site Selection: Why It Matters for Enrollment Success
Site selection is the single biggest lever clinical operations teams have over enrollment timelines. Studies show that up to 30% of investigator sites fail to enroll a single patient, and roughly half underperform against targets. The cost of a poor site choice compounds quickly—delayed enrollment extends timelines, inflates budgets, and can jeopardize regulatory submission windows.
A growing ecosystem of specialized consultants and technology platforms now exists to address this challenge, offering data-driven feasibility assessments, investigator databases, and predictive analytics that go far beyond traditional manual site identification.
What Site Selection Consultants Actually Do
The scope of services varies across providers, but core capabilities typically include:
- Feasibility Assessment
- Evaluating potential sites against protocol-specific criteria—patient population density, competitive trial landscape, regulatory readiness, and past performance metrics.
- Investigator Identification
- Matching principal investigators to trials based on therapeutic expertise, enrollment track record, and publication history. Leading platforms like Citeline Sitetrove maintain databases of over 530,000 investigators across 190,000+ sites.
- Country & Region Strategy
- Advising on optimal geographic distribution to balance regulatory requirements, patient diversity, and operational cost—especially critical for global Phase III programs.
- Site Activation Support
- Streamlining IRB/ethics submissions, contract negotiations, and start-up logistics to reduce time from site selection to first patient enrolled.
Full-Service CROs vs. Specialist Consultants
The landscape divides broadly into two categories:
| Type | Examples | Best For |
|---|---|---|
| Full-service CROs with site selection | IQVIA, Parexel, PPD (Thermo Fisher), Medpace | Sponsors wanting integrated trial management |
| Specialist feasibility platforms | Citeline Sitetrove, WCG ClinSphere | Sponsors needing data-driven site intelligence |
| Regional/therapeutic niche CROs | Novotech (Asia-Pacific), Ergomed (rare disease), CTI (gene therapy) | Trials requiring deep regional or disease expertise |
Key Trends Shaping Site Selection
AI-Powered Feasibility
Platforms are increasingly using machine learning to predict site performance based on historical enrollment data, investigator publication records, and real-world patient data. WCG ClinSphere reports doubled feasibility response rates compared to industry averages through AI-enhanced outreach.
Decentralized and Hybrid Trial Models
The rise of decentralized clinical trials (DCTs) is shifting site selection criteria. Consultants now evaluate sites not just on traditional metrics but on their capacity for remote monitoring, e-consent, and home health visits.
Diversity-Focused Site Selection
Following FDA guidance on diversity in clinical trials, site selection consultants are integrating demographic and social determinants of health data to help sponsors meet representation goals. Citeline and IQVIA both offer patient-centric site mapping tools that overlay disease prevalence with demographic data.